How advances in molecular understanding are shaping Parkinson's disease classification, patient stratification, and the future of personalized care Parkinson’s disease has historically been diagnosed and classified primarily according to clinical features. However, advances in genetics, molecular biomarkers, and our ...

Highlights from the European Academy of Neurology (EAN) 2026 Congress included new phase 3 data in ocular myasthenia gravis, emerging migraine treatments, longer-term results in multiple sclerosis, and advances in deep brain stimulation for Parkinson’s disease. The 12th Congress of the ...

Leading Alzheimer's disease experts share the therapeutic and research developments they believe had the greatest potential to transform diagnosis, treatment and prevention at the Alzheimer's Association International Conference (AAIC) 2026. The Alzheimer's Association International Conference (AAIC) 2026 showcased advances across the Alzheimer's ...

Could NLRP3 be the missing link between amyloid pathology and tau-mediated neurodegeneration? Dr Gennaro Pagano explains how insights from the GRADUATE trial is informing the next generation of Alzheimer's disease therapies and advancing our understanding of neuroinflammation. https://touchmedicalmedia-1.wistia.

Prof. Arcadi Navarro discusses BBRC's largest-ever presence at AAIC, the growing role of biomarkers and personalized risk prediction, and why prevention is becoming the future of Alzheimer's disease research. Introduction We spoke with Prof. Arcadi Navarro, Professor of Genetics and ...

Dr Klaus Dugi discusses the first-in-human data for VNA-318, the rationale for targeting cellular energy metabolism in Alzheimer's disease, and how improving mitochondrial function could offer both symptomatic and disease-modifying benefits. We spoke with Klaus Dugi, Chief Executive Officer of ...

Prof. John-Paul Taylor discusses the phase 2b RewinD-LB findings, lessons learned from the neflamapimod programme, and the next steps towards precision medicine in dementia with Lewy bodies We spoke with Prof. John-Paul Taylor, Newcastle University, Newcastle upon Tyne, UK, at ...

Prof. George Grossberg discusses the unmet need in agitation associated with Alzheimer's disease, the rationale behind the phase 3 ADAGIO studies, and the evolving role of biomarkers and caregivers in improving patient care. We spoke with Prof. George Grossberg, Saint Louis ...

Large real-world study highlights important ethnoracial differences in amyloid positivity and their implications for diagnosis, treatment and clinical trial access As amyloid biomarkers become central to Alzheimer's disease diagnosis and treatment, a new analysis from the New IDEAS (Imaging Dementia—...